Audio Medica - Medical Audio News Interviews & Podcasts

Archive for January, 2007

Miscarriage Risk in Women with Low Body Mass Index

By admin ⋅ January 26, 2007 ⋅ Post a comment

PAT DOYLE, London School of Hygiene and Tropical Medicine

REFERENCE: BJOG 2007 114:170
Underweight women were found to be at increased risk of miscarriage in a study published in the British Journal of Obstetrics and Gynaecology. A team from the London School of Hygiene and Tropical Medicine conducted a survey by questionnaire of 6 000 women among whom 600 had a first trimester miscarriage. Using a “case-control” method of comparison it emerged that women with a body mass index below 18.5 had a 70 per cent increase in their risk of miscarriage. Peter Goodwin heard more about the study from Pat Doyle of the London School of Hygiene and Tropical Medicine.

Audio Journal of Global Health Issues: Three-Class Antiretroviral Therapy for HIV Not Appropriate: Results from the FIRST Study">Audio Journal of Global Health Issues: Three-Class Antiretroviral Therapy for HIV Not Appropriate: Results from the FIRST Study

By admin ⋅ January 19, 2007 ⋅ Post a comment

RODGER MACARTHUR, Wayne State University, Detroit

REFERENCE: Lancet 2006; 368: 2125-35
A three-class HIV antiretroviral therapy is not necessary, according to data published in the Lancet. The FIRST study had three arms which included non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), or both, all in the presence of nucleoside reverse transcriptase inhibitors. Derek Thorne heard more from Rodger MacArthur of Wayne State University in Detroit.

Audio Journal of Cardiovascular Medicine: Telomere Length Predicts Coronary Heart Disease Risk and Statin Response">Audio Journal of Cardiovascular Medicine: Telomere Length Predicts Coronary Heart Disease Risk and Statin Response

By admin ⋅ January 19, 2007 ⋅ Post a comment

NILESH SAMANI, Glenfield Hospital, Leicester

REFERENCE: Lancet 2007; 369:107
A new genetic test could help predict which individuals will develop coronary heart disease among those with similar conventional risk factors. The length of the terminating structures of chromosomes, telomeres, can be used to predict cardiovascular mortality in middle-aged men, according to a study from Leicester in the UK which analysed blood samples collected for the West of Scotland Primary Prevention Study, (WOSCOPS). Nilesh Samani gave Helen Morant the details.

Audio Journal of Global Health Issues: Microfinance Helps Cut Domestic Violence in Rural South Africa">Audio Journal of Global Health Issues: Microfinance Helps Cut Domestic Violence in Rural South Africa

By admin ⋅ January 17, 2007 ⋅ Post a comment

CHARLOTTE WATTS, London School of Hygiene and Tropical Medicine

REFERENCE: Lancet 2006; 368: 1973-83
A large and groundbreaking study has shown that microfinance, combined with a gender and HIV training scheme, can help reduce domestic violence among poor women living in rural South Africa. Charlotte Watts of the London School of Hygiene and Tropical Medicine told Derek Thorne about the IMAGE study.

Audio Journal of Oncology in Advance - January 15th, 2007 - HERA Study Results Confirm Trastuzumab Benefit in HER2 Positive Early Breast Cancer

By admin ⋅ January 17, 2007 ⋅ Post a comment

IAN SMITH, Royal Marsden Hospital, London

REFERENCE: Lancet 369:29
Confirmation of the life-extending benefits of trastuzumab adjuvant therapy for early breast cancer has been published recently in the Lancet. Ian Smith gave Peter Goodwin three-year follow up results from the Herceptin Adjuvant (HERA) Study conducted among 3,000 women in Europe.

To listen this episode please go to ASCO Audio Journal of Oncology in Advance Presentations.

Audio Journal of Medicine: Circulating Markers Herald Onset of Preeclampsia">Audio Journal of Medicine: Circulating Markers Herald Onset of Preeclampsia

By admin ⋅ January 8, 2007 ⋅ Post a comment

RICHARD LEVINE, National Institutes of Health, Bethesda

REFERENCE: N Engl J Med 2006; 355:992
In pregnant women circulating levels of the anti-angiogenic substances: soluble endoglin and soluble Flt-1 herald the onset of preeclampsia, according to a publication in the New England Journal of Medicine. Richard Levine told Peter Goodwin about his group’s findings from the Calcium for Preeclampsia Prevention Trial which give hope of designing molecularly targeted drugs to treat preeclampsia or of spotting the disease early.

Audio Journal of Oncology in Advance - January 1st, 2007 - Reporting from San Antonio Breast Cancer Symposium, December 14-17, 2006

By admin ⋅ January 2, 2007 ⋅ Post a comment

Dennis Slamon

George Peoples

James Holland

Massimo Christofanilli

Trastuzumab: Mature Results in Early Breast Cancer Show Superiority

REFERENCE: San Antonio Breast Cancer Symposium 2006, Abstract: 52
DENNIS SLAMON, University of California, Los Angeles
Adjuvant therapy regimens containing trastuzumab have proved superior to those with cytotoxic chemotherapy agents alone, used without the new molecular therapy. Mature results from the massive BCIRG 006 phase III randomized trial looking at adjuvant doxorubicin, cyclophosphamide, docetaxel with or without trastuzumab were presented in San Antonio by Dennis Slamon, who discussed the details with Peter Goodwin.

HER2 Peptide Vaccine Prevents Breast Cancer Recurrence

REFERENCE: San Antonio Breast Cancer Symposium 2006, Abstract: 4
GEORGE PEOPLES, Brook Army Medical Center, Houston
A vaccine to prevent breast cancer has shown early success in a study reported in San Antonio. A group from Houston presented results from the first trial of vaccination against recurrent breast cancer using the E75 single peptide vaccine. George Peoples told Karen Regester how the vaccine improved progression free survival.

Virus Cause of Breast Cancers?

REFERENCE: San Antonio Breast Cancer Symposium 2006, Abstract: 6
JAMES HOLLAND, Mount Sinai School of Medicine, New York
A virus may be the cause of human breast cancer, according to James Holland, who gave the San Antonio conference his latest findings implicating human mammary tumor virus as a leading cause of breast cancer. He discussed the data with Peter Goodwin.

Lapatinib Shows Promise as Therapy For Inflammatory Breast Cancer

REFERENCE: San Antonio Breast Cancer Symposium 2006, Abstract: 1
MASSIMO CHRISTOFANILLI, MD Anderson Cancer Center, Houston
Targeted therapy may be the best way to combat aggressive inflammatory breast cancer. Massimo Christofanilli and his colleagues selected patients with HER2neu and EGFR expression for therapy with the dual targeted inhibitor, lapatinib. Benefits were apparent within the first two weeks of treatment.